Cargando…

Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omma, Ahmet, Armaǧan, Berkan, Güven, Serdar Can, Sandıkçı, Sevinç Can, Çolak, Seda, Yücel, Çiǧdem, Küçükşahin, Orhan, Erden, Abdulsamet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667615/ https://www.ncbi.nlm.nih.gov/pubmed/34912764 http://dx.doi.org/10.3389/fped.2021.788864

Ejemplares similares

COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study
por: Güven, Serdar Can, et al.
Publicado: (2021)

Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
por: Omma, Ahmet, et al.
Publicado: (2017)

The Possible Relation of Demodex and Facial Erythema in Connective Tissue Diseases
por: Erden, Abdulsamet, et al.
Publicado: (2023)

Antineutrophil cytoplasmic antibody positivity and clinical implications in COVID-19
por: Güven, Serdar Can, et al.
Publicado: (2022)

COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature
por: ARMAĞAN, Berkan, et al.
Publicado: (2022)

Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study
por: Omma, Ahmet, et al.
Publicado: (2021)

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Correction to: COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

A single center experience of intravenous immunoglobulin treatment in Covid-19
por: Omma, Ahmet, et al.
Publicado: (2021)

Effects of breast milk on Behçet’s disease clinical features
por: KONAK, Hatice Ecem, et al.
Publicado: (2023)

Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease
por: Omma, Ahmet, et al.
Publicado: (2018)

Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience
por: Apaydin, Hakan, et al.
Publicado: (2022)

Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle/Black Sea Region of Turkey (in Çorum region)
por: Karaaslan, Y, et al.
Publicado: (2015)

Do the European League Against Rheumatism (EULAR) Sjögren’s syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren’s syndrome?
por: Omma, Ahmet, et al.
Publicado: (2017)

A case of human leukocyte antigen B27 positive reactive arthritis associated with severe acute respiratory syndrome coronavirus 2 infection
por: Apaydin, Hakan, et al.
Publicado: (2021)

An investigation of thiol/disulfide homeostasis in patients with Behçet’s disease
por: Sandikci, Sevinc Can, et al.
Publicado: (2019)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience
por: Ateş, İhsan, et al.
Publicado: (2021)

How long is the diagnosis of Familial Mediterranean Fever (FMF) delayed in a region where FMF is common in Turkey?
por: Karaaslan, Y, et al.
Publicado: (2015)

Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra
por: Celebi, Zeynep Kendi, et al.
Publicado: (2014)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study
por: Ates, Ihsan, et al.
Publicado: (2023)

False positivity of Rose Bengal test in patients with COVID-19: case series, uncontrolled longitudinal study
por: Gemcioglu, Emin, et al.
Publicado: (2020)

Increased psoriasis frequency in patients with familial Mediterranean fever
por: Erden, Abdulsamet, et al.
Publicado: (2018)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients
por: BODAKÇİ, Erdal, et al.
Publicado: (2021)

Colchicine Intolerance: Does the Pharmaceutical Preparation Matter?
por: İlgen, Ufuk, et al.
Publicado: (2021)

Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis
por: Alpay-Kanitez, Nilüfer, et al.
Publicado: (2020)

A single-center rheumatology experience of sarcoidosis: Observations from 70 patients
por: Konak, Hatice Ecem, et al.
Publicado: (2023)

Colchicine intoxication: a report of two suicide cases
por: Erden, Abdulsamet, et al.
Publicado: (2013)

An evaluation of the results of convalescent plasma therapy applied to pregnant women diagnosed as COVID-19-positive in a pandemic center: A prospective cohort study
por: EROL, Seyit Ahmet, et al.
Publicado: (2022)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
por: Calligaris, Lorenzo, et al.
Publicado: (2007)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

A Hypothesis Regarding Neurosecretory Inhibition of Stress Mediators by Colchicine in Preventing Stress-Induced Familial Mediterranean Fever Attacks
por: Korkmaz, Cengiz, et al.
Publicado: (2022)

Can endocan serve as a molecular “hepatostat” in liver regeneration?
por: Yazici, Sinan Efe, et al.
Publicado: (2023)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
por: Köhler, Birgit Maria, et al.
Publicado: (2018)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gb6e7tidv080ros119bbonpfbg